Small and Steatotic Hepatocellular Carcinoma

Small and Steatotic Hepatocellular Carcinoma : a Distinctive Radiological Variant With Improved Outcome After Percutenous Ablation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03428321

Enrollment

238

Registered

2018-02-09

Start date

2015-01-01

Completion date

2019-12-30

Last updated

2020-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCC

Keywords

Microwave ablation, Percutaneous thermalablation, High risk location, Articifial pneumothorax, Lipiodol marked, Prognostic factor

Brief summary

Percutaneous thermoablation in an effective local curative treatment in patients with cirrhosis and HCC smaller than 3 cm in diameter (BCLC 0-A). Around 30% of HCC patients referred for percutaneous ablation were regarded as non-feasible because of a difficult-at risk location or undetectable nodules. We used percutaneous thermoablation to treat HCC on high risk locations (subcapsular or liver dome) with or without lipiodol marked (for undetectable HCC). No clinical study has been published so far to compare percutaneous thermoablation of HCC on liver dome CT guided with artificial pneumothorax and lipiodol marked, and percutaneous thermoablation of HCC guided by ultrasonography (non subcapsular, distent form diaphragm). This retrospective study evaluate the overall survival, the local tumor progression or distant liver progression after percutaneous ablation for HCC and determine prognostic factors.

Detailed description

We performed 412 percutaneous thermoablations on 238 patients for HCC between January 2015 and November 2019. All thermoablation procedures were performed percutaneously under ultrasound or CT guidance, with ou without artificial pneumothorax or ascites, with ou without lipiodol marked. Purposes: * Tumor response upon mRECIST criteria * Progression-free survival * Overall survival * Local tumor progression * Distent liver progression * Prognostic factors

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* HCC according to histological examination or Barcelona criteria * BCLC0 or A * Measurable targets according to mRECIST v1.1 * Child A or B7 cirrhosis * HCC \< 4 cm, \< 3 nodules, Age ≥ 18 years * No extrahepatic metastasis, no vascular invasion * Performance status 0 or 1 * Thrombocytes ≥ 50 000/mm3, TP \> 50%

Exclusion criteria

* Follow-up \< 1month * Lobar/main portal venous thrombus * Abundant ascites * Antecedent of bilio-digestive anastomosis or endoscopic sphincterotomy * Combined treatment with embolization or chemo-embolization

Design outcomes

Primary

Measure	Time frame	Description
Thermal ablations	1 day	Evaluation of thermal ablations (radiofrequency and microwave ablation)

Countries

France

Outcome results